LogicBio Therapeutics (OTCMKTS:LOGC) Shares Gap Down – Should You Sell?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report)’s stock price gapped down prior to trading on Tuesday. The stock had previously closed at $13.80, but opened at $12.97. LogicBio Therapeutics shares last traded at $12.92, with a volume of 3,302 shares changing hands.

LogicBio Therapeutics Trading Down 0.8%

The business has a 50 day simple moving average of $14.86 and a two-hundred day simple moving average of $10.51. The company has a market cap of $589.92 million, a PE ratio of -17.67 and a beta of 2.11. The company has a current ratio of 1.43, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.25). The business had revenue of $32.20 million during the quarter, compared to analysts’ expectations of $32.20 million.

About LogicBio Therapeutics

(Get Free Report)

LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease. The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery.

Recommended Stories

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.